Freedman, S. ., Hercinovic, A. ., Wallace, D. K., Kraker, R. ., Li, Z. ., Bhatt, A. ., … Good, W. V. (2022). Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes. Ophthalmology, 129(10), 1120-1128. 10.1016/j.ophtha.2022.05.019 (Original work published 2022)
Amit Bhatt
Wallace, D. K., Hercinovic, A. ., Freedman, S. ., Crouch, E. ., Bhatt, A. ., Hartnett, E. ., … Investigator Group, P. E. D. . (2023). Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity. Journal of the American Association for Pediatric Ophthalmology and Strabismus, 27(1), 10.e1-10.e8. 10.1016/j.jaapos.2022.11.020 (Original work published 2023)
Wallace, D. K., Kraker, R. ., Freedman, S. ., Crouch, E. ., Bhatt, A. ., Hartnett, E. ., … Investigator Group, P. E. D. . (2020). Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmology, 138(6), 698-701. 10.1001/jamaophthalmol.2020.0334 (Original work published 2020)
Wallace, D. K., Kraker, R. ., Freedman, S. ., Crouch, E. ., Hutchinson, A. ., Bhatt, A. ., … Investigator Group, P. E. D. . (2017). Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA Ophthalmology, 135(6), 654-656. 10.1001/jamaophthalmol.2017.1055 (Original work published 2017)